TOM Trial
Testosterone in Older Men with Mobility Limitations (Basaria et al., NEJM 2010)
Evidence grade 4 of 5, Strong. Read how the Atlas grades evidence.
1 human trial, about 1 studies, 209 participants men, mean age ~74, with mobility limitation. The written rationale for this grade is still being prepared.
- FDA
- Investigator-initiated RCT (stopped early)
Reference only. Not medical advice.
What can go wrong
The testosterone arm had roughly 23 cardiovascular-related adverse events versus 5 on placebo, prompting the safety board to stop the trial. The population was frail and elderly with high baseline cardiovascular risk, and doses were on the higher side.
This is something to take to a clinician. The Atlas can tell you what is known about tom trial in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
The TOM trial randomized older men (mean age ~74) with mobility limitations and a high burden of chronic disease to testosterone gel or placebo, primarily to test leg-strength and physical-function benefit. It was halted early by its data safety monitoring board because the testosterone group experienced significantly more cardiovascular-related adverse events. Although small (209 men) and not designed to detect cardiovascular outcomes, TOM was the spark that ignited a decade of debate over TRT and heart risk.
The trial stopped early when older, frail men on testosterone had more cardiovascular events.
What people take it for
What it is taken for. Approval, where it exists, covers only some of these.
How it works
TOM aimed to test whether raising testosterone improves muscle strength and mobility in frail older men. The cardiovascular signal was an unplanned safety finding, not the trial's purpose.
Why TOM must be read carefully
TOM enrolled an unusually frail, comorbid, elderly population and used relatively HIGH testosterone doses, with some men reaching supraphysiological levels. Its cardiovascular events were a heterogeneous mix (including peripheral edema and arrhythmia, not just MIs), the absolute numbers were small, and the trial was never powered for cardiovascular outcomes. It generated a hypothesis - it did not prove TRT causes heart attacks.
Safety in detail
This intervention involves significant physiological effects and requires evaluation and monitoring by a qualified physician. Self-administration without medical oversight carries documented health risks.
Replacement is not the same as a cycle
TOM used doses up to 150 mg/day of gel, pushing some frail elderly men toward supraphysiological levels - a key reason its safety signal cannot be generalized to careful physiological replacement.
What people get wrong
Often saidTOM proved testosterone causes heart attacks
ActuallyTOM generated a SAFETY HYPOTHESIS in a small, frail, high-dose population - it did not establish causation, and the later, far larger TRAVERSE trial did not confirm an excess of heart attacks or strokes.
Who profits, and who pushes back
Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.
How we got here
Published in NEJM in 2010, TOM was among the first randomized signals of possible cardiovascular harm from testosterone. Combined with two 2013-2014 observational studies, it drove the FDA's 2015 label change and ultimately the mandate for TRAVERSE.
- ~2005-2009TOM conducted in frail older men
- 2010Stopped early; results in NEJM
- 2013-2014Observational CV-harm studies amplify concern
- 2015FDA label change and TRAVERSE mandate follow
- 2023TRAVERSE largely fails to confirm the heart-attack signal
What the trials could not show
Limits of the studies themselves, as distinct from limits of the treatment.
- Very small (209); not powered or designed for CV outcomes; heterogeneous, loosely defined CV event categories; frail high-risk population not generalizable; relatively high/variable dosing; early termination inflates uncertainty around the effect estimate.
What we do not know
- Was the signal driven by dose, frailty, or chance?
- How much did edema/arrhythmia (vs ischemic events) drive the result?
At a glance
- Design
- Double-blind, placebo-controlled RCT, stopped early
- N
- 209
- Mean age
- ~74
- Agent
- Testosterone gel, doses up to 150 mg/day (relatively high)
- Primary endpoint
- Leg-press strength and physical function
- Reason stopped
- Excess cardiovascular adverse events in testosterone arm
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about TOM Trial. A short entry is not a safe entry.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
Sources
The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.
The studies that matter
TOM trial (Basaria et al., NEJM)2010
23 cardiovascular-related events in the testosterone group vs 5 in placebo over the trial; significant strength gains were also observed before early termination